Kailera Therapeutics, Inc.'s (NASDAQ:KLRA) Lock-Up Period Will End on October 14th

Key Points

• Kailera Therapeutics’ lock-up period ends October 14, allowing insiders and major shareholders to sell shares. The company issued 39.06 million shares in its April public offering, which raised $625 million.
• Analyst sentiment is generally positive, with an average rating of “Moderate Buy” and an average price target of $42.75, despite Weiss Ratings initiating coverage with a “Sell” rating.
• KLRA opened at $10.83, well below its 50-day moving average of $15.41, and recently reported a quarterly loss of $1.09 per share versus the expected $0.74 loss.

Kailera Therapeutics' (NASDAQ:KLRA - Get Free Report) lock-up period is set to end on Wednesday, October 14th. Kailera Therapeutics had issued 39,062,500 shares in its public offering on April 17th. The total size of the offering was $625,000,000 based on an initial share price of $16.00. After the expiration of Kailera Therapeutics' lock-up period, major shareholders and company insiders will be able to sell their shares of the company.

Analyst Ratings Changes

Separately, Weiss Ratings initiated coverage on Kailera Therapeutics in a research report on Friday, August 14th. They issued a "sell (d)" rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $42.75.

Kailera Therapeutics Price Performance

Shares of Kailera Therapeutics stock opened at $10.83 on Wednesday. The business's fifty day simple moving average is $15.41. The firm has a market cap of $1.40 billion and a P/E ratio of -0.00. Kailera Therapeutics has a 12 month low of $9.85 and a 12 month high of $28.23.

Kailera Therapeutics (NASDAQ:KLRA - Get Free Report) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by ($0.35). Equities research analysts predict that Kailera Therapeutics will post -3.89 EPS for the current fiscal year.

Institutional Trading of Kailera Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Atlas Venture Life Science Advisors LLC acquired a new position in shares of Kailera Therapeutics in the second quarter valued at approximately $113,923,000. Wellington Management Group LLP bought a new stake in Kailera Therapeutics in the 2nd quarter valued at $64,308,000. Frazier Life Sciences Management L.P. acquired a new position in Kailera Therapeutics in the 2nd quarter worth $24,233,000. State Street Corp acquired a new position in Kailera Therapeutics in the 2nd quarter worth $19,126,000. Finally, Squarepoint Ops LLC bought a new position in Kailera Therapeutics during the 2nd quarter worth about $993,000.

About Kailera Therapeutics

Kailera Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines for obesity and other chronic metabolic diseases. The company's research is centered on therapies designed to address weight management and related health conditions.

Kailera's pipeline includes ecnoglutide, an investigational, long-acting glucagon-like peptide-1 (GLP-1) receptor agonist being evaluated for potential use in obesity and metabolic disorders. The company continues to advance clinical development and assess additional opportunities in the metabolic disease sector.

Kailera Therapeutics is focused primarily on research and development activities, with its programs intended for potential commercialization in international markets subject to clinical, regulatory and other approvals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.